Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.63), $0.17 better than the analyst estimate of ($0.80).

“I am pleased with the significant progress we have made in the third quarter across our commercial, regulatory, and clinical initiatives,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We are preparing for a potential launch of lumateperone in the first quarter of 2020, and continue to advance our clinical programs, including our PDE1 program and our Phase 3 trial evaluating lumateperone as an adjunctive therapy in bipolar depression.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.